Adalimumab is used to treat Crohn’s disease. Tumour necrosis factor alpha (TNF-α) causes inflammation and is thought to play a central role in Crohn’s disease. Adalimumab is a human-derived genetically engineered drug that binds to TNF-α, inhibiting its activity and thereby reducing inflammation.

Is it licensed and approved by NICE?

Yes – it is licensed to treat severe active Crohn’s disease in patients who have not responded to steroids and/or an immunosuppressant (such as mercaptopurine), or who are intolerant to or have medical contraindications to such therapy. NICE have approved its use for up to one year in the first instance and thereafter only following re-assessment by a specialist.

Ideally patients should be treated with either a mercaptopurine or methotrexate for the FIRST 6 MONTHS of treatment with adalimumab to improve its effect on Crohn’s disease. Thereafter treatment with mercaptopurine or methotrexate may be stopped but this is subject to discussion.

Who should avoid adalimumab?

Patients with TB or other severe infections, sepsis, abscesses and opportunistic infections (patient should have a CXR to exclude TB)
Patients with multiple sclerosis or optic neuritis
Patients with moderate or severe heart failure
Patients with a history of hypersensitivity to adalimumab
Patients towards the end of pregnancy or breast feeding (stop adalimumab before last trimester)
Patients with history of lymphoma or cancer

How to give adalimumab

Induction: 160mg at week 0 (either as four injections in one day or two injections per day for two consecutive days) followed by 80mg at week 2. If patient is NOT taking immunosuppression, then pre-treat with IV hydrocortisone 100mg & oral chlorphenamine 4mg 30 minutes before starting adalimumab.
Maintenance treatment: 40mg alternate weeks via subcutaneous injection. If patients experience decrease in response dose may be increased to 40mg every week.

Adverse effects

All patients should be observed for at least 1-2 hours after induction doses for side effects:

Acute infusion reaction (4%). Usually occurs during first or second dose. If develop shortness of breath or itchy rash, please tell the nurse or doctor.
Other side-effects include headache, abdominal pain, nausea (20-30%)
Serious infections (4%), including TB

At Digestive Health City & Docklands, we work hard to provide our patients with top-class care. You will enjoy friendly, fast and modern treatment by a highly experienced gastroenterologist. We carefully review patient satisfaction and feedback, and at Digestive Health we are continuously making improvements to our services, ensuring the highest level of care possible.

Get In Touch

Secretarial Hours

Monday – Friday
9am – 5pm

Call Us

0203 727 6179


@dradamharris - 2 weeks

Was pleased to organise and speak at the 3rd annual “Update in Medicine for GPs” event that took place on Saturday…

@dradamharris - 5 months

Listen to my podcast on Helicobacter pylori at

© 2021 Digestive Health City & Docklands. All Rights Reserved.

Designed and Developed By